Delivery systems for molecular vaccination

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 1, 2000, Pages 37-54

  Sheikh, Nadeem A ^a   Al Shamisi, Mariam ^b   Morrow, W John W ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Antigen; Copolymer; Cytokine; Saponin

Indexed keywords

ADJUPHOS; ALUMINUM HYDROXIDE; ALUMINUM SALT; ANTIGEN; BACTERIAL DNA; BIOPOLYMER; CELL WALL SKELETON; COPOLYMER; CRL 1005; CYTOKINE; ENTEROTOXIN; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; ISCOM; ISCOPREP 7.03; L 121; LIPOSOME; MUROCTASIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHORYL LIPID A; POLYGLACTIN; PROVAX; QS 21; QUIL A; REHYDRAGEL; SAF; SAPONIN; TITERMAX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

ANTIGEN PRESENTATION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; EMULSION; IMMUNOTHERAPY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM; ANIMALS; ANTIGENS; CYTOKINES; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; EMULSIONS; FREUND'S ADJUVANT; HUMANS; LIPOSOMES; MICROSPHERES; PEPTIDES; PLANTS, EDIBLE; PLANTS, GENETICALLY MODIFIED; POLYMERS; SAPONINS; T-LYMPHOCYTE SUBSETS; VACCINES; VACCINES, DNA;

BACTERIA (MICROORGANISMS);

EID: 0034057279     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Murray CJL, Lopez A (Eds): The Global Burden of Disease and injury. Harvard University Press (1996). A comprehensive report detailing the cost of disease and presenting valid statistical analyses of the socio-economic impact of disease.
2. Bloom BR, Widdus R: Vaccine visions and their global impact Nature Med (1998) 4(Suppl 5):480-484.
3. Singh M, O'Hagan D: Advances In vaccine adjuvants. Nature Biotechnol (1999) 17:1075-1081.
4. Sheikh N, Rajananthanan P, Morrow WJW: Immunological adjuvants: Mechanisms of action and clinical applications. Exp Opin Invest Drugs (1996) 5:1079-1099.
5. Vogel FR, Powell MF: A compendium of vaccine adjuvants and excipients. In: Vaccine Design, the Subunit Approach. Powell MF, Newman MJ (Eds), Plenum Press (1995):141-228. A definitive text detailing different adjuvants, their structures, trade names and their historical development.
6. Seeber SJ, White JL, Hem SL: Predicting the absorption of proteins by aluminium-containing adjuvants. Vaccine (1991) 9:201-203.
7. Gupta RK, Relyveld EH: Adverse reactions after injection of adsorbed diphtheria-pertussis-tetanus (DTP) vaccine are not due only to pertussis organisms or pertussis components In the vaccine. Vaccine (1991) 9:699-702.
8. Hem SL, White JL: Strucure and properties of aluminium-containing adjuvants. In: Vaccine Design, the Subunit Approach. Powell MF, Newman MJ (Eds), Plenum Press (1995):249-276.
9. Potter M, Boyce CR: Induction of plasma cell neoplasms in BALB/c strain mice with mineral oil and mineral oil adjuvants. Nature (1962) 193:1086-1087. An early report showing the toxic side effects associated with Freund's type adjuvants (see also reference [15]).
10. Skea DL, Barber BH: Studies of the adjuvant-independent antibody response to immunotargeting. Target structure dependence, Isotype distribution, and induction of long term memory. J Immunol (1993) 151:3557-3568.
11. Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott G, Higgins KW, Duntop N, Scandella CJ, Eichberg JW, Steimer KS: Native but not denatured recombinant human immunodeficincy virus type I gp120 generates broad spectrum neutralizing antibodies In baboons. J Virol (1992) 66:172-182.
12. Sanchez-Pescador L, Burke RL, Ott G, Van Nest G: The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol (1988) 141:1720-1727.
13. Schirmbeck R, Reimann J: Targeting of exogenous protein antigens to a novel endosomal processing pathway for class I-restricted presentation. Behring Inst Mitt (1994) 95:14-22.
14. Stewart-Tull DES: Recommendations for the assessment of adjuvants (Immunopotentiators). In: Immunological Adjuvants and Vaccines. NATO ASI Series A: Life Sciences (1988) 179:213-216.
15. Pearson CM: Development of arthritis, periarthritis and periostitis in rats given adjuvant. Proc Soc Exp Biol Med (1956) 91:95-101. An early report showing the toxic side effects associated with Freund's type adjuvants (see also reference [9]).
16. Murray R, Cohen P, Hardegree MC: Mineral oil adjuvants: Biological and chemical studies. Ann Allergy (1972) 30:146-151.
17. Maclennan R, Shofield FD, Pittmann M: Immunization against neonatal tetanus in toxoid in New Guinea: Antitoxin responses of pregnant women to adjuvant and plain toxolds. Bull WHO (1965) 32:683-697.
18. Ogonuki H, Hashizume S, Takashashi B: Preparation and laboratory tests of oil-adjuvant cholera vaccine. Bull WHO (1967) 37:729-736.
19. Byars N, Allison AC: Syntex adjuvant formulation. In: The Theory and Practical Application of Adjuvants. Stewart-Tull DES (Ed), J Wiley & Sons (1995):203-212.
20. Hunter R, Strickland F, Kezdy F: The adjuvant activity of non-ionic block polymer surfactants I. The role of hydrophlle-lipophile balance. J Immunol (1981) 127:1244-1250.
21. Adam A, Clorbaru R, Petit JF, Lederer E: Isolation and properties of a macromolecular, water-soluble, immunoadjuvant fraction from the cell wall of Mycobacterium smegmatis. Proc Natl Acad Sci USA (1972) 69:851-854.
22. Ellouz F, Adam A, Ciorbaru R, Lederer A: Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun (1974) 59:1317-1325.
23. Kotani S, Watanabe Y, Kinoshita F, Shimono T, Morisaki I: Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids. Biken J (1975) 18:105-111.
24. Krueger JM, Pappenheimer JR, Kamovsky ML: The composition of sleep-promoting factor isolated from human urine. J Biol Chem (1982) 257:1664-1669.
25. Takada H, Kotani S: Muramyl dipeptlde and deriatives. In: The Theory and Practical Application of Adjuvants. Stewart-Tull DES (Ed), J Wiley & Sons (1995):171-202.
26. Otani T, Une T, Osada Y: Stimulation of non-specific resistance to infection by muroctasin. Arzneimittelforschung (1988) 38:969-976.
27. Ono Y, Iwasaki T, Sekiguchi M, Onodera T: Subacute toxicity of muroctasin In mice and dogs. Arzneimittelforschung (1988) 38:1024-1027.
28. Ichihara N, Kanazawa R, Sasaki S, Ono K, Otani T, Yamaguchi F, Une T: Phase I study and clinical pharmacological study of muroctaskn. Arzneimittelforschung (1988) 38:1043-1069.
29. Lidgate DM, Byars NE: Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines. In: Vaccine design, the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds), Plenum Press (1995):313-324.
30. Johnson AG, Gains S, Landy M: Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody responses to protein antigens by the purified polysaccharides. J Exp Med (1956) 103:225-246.
31. Johnson Ag: Adjuvant action of bacterial endotoxins on the primary antibody response. In: Bacterial Endotoxins. Landy M, Braun W (Eds), Rutgers University Press (1964):252-262.
32. Munoz J: Effects of bacteria and bacterial products on antibody response. In: Advances in immunology. Dixon FJ, Kunkel HG (Eds), Academic Press (1964):397-404.
33. Ribi E, Parker R, Strain SM, Mizuon Y, Nowotny A, Von Eschen KB, Cantrell JL, Mclaughlin CA, Hwang KM, Goren MB: Peptides as requirements for immunotherapy of the gulna pig line 10 tumor with endotoxins. Cancer Immunol Immunother (1979) 7:43-58.
34. Qureshi N, Takayama K, Ribi E: Purification and structural determination of non-toxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem (1982) 257:11808-11815.
35. Ribi E, Cantrell JL, Takayama K, Ribi HO, Myers KR, Qureshi N: Modulation of humoral and cell mediated immune responses by a structurally established non-toxic lipid A. In: Immunobiology and Immunopharmacology of Bacterial Endotoxins. Svetivanyl A, Friedman H (Eds), Plenum Press, New York (1986):407-420.
36. Rudbach JA, Johnson DA, Ulrich JT: Ribi adjuvants: Chemistry, biology and utility in vaccines for human and veterinary medicine. In: The Theory and Practical Application of Adjuvants. Stewart-Tull DES (Ed), J Wiley & Sons (1995):287-313.
37. Zhou F, Huang L: Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped In liposomes. Vaccine (1993) 11:1394-1144. One of the first studies showing that CTL could be induced against soluble protein when formulated with a delivery vehicle.
38. Esquivel F, Taylor CE, Baker PJ: Differential sensitivity of CD8+ suppressor and cytotoxic T-lymphocyte activity to bacterial monophosphoryl lipid A. Infect Immun (1991) 59:2994-2998.
39. Pietrobon PJF: Liposome design and vaccine development In: Vaccine Design, the Subunit Approach. Powell MR, Newman MJ (Eds), Plenum Press (1995):347-361.
40. Azuma I, Kanetsuna F, Taniyama T, Yamamura Y, Hori M: Adjuvant activity of mycobacterial fractions. I Purification of an in vivo adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroides 131 and Corynebacterium diptheriae PWB. Biken J (1975) 18:1-13.
41. White RG: The adjuvant effect of microbial products on the immune response. Annu Rev Microbiol (1976) 30:579-600.
42. O'Nelll GJ, Henderson DC, White RG: The role of anaerobic coryneforms on specific and non-specific immunological reactions. I. Effect of particle clearance and humoral and cell-mediated immunological responses. Immunology (1973) 24:977-995.
43. Berek JS, Cantrell JL, Lichtenstein AK, Hacker NF, Knox RM, Nieberg RK, Poth T, Elashcff RM, Lagasse LD, Zighelboim J: immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model. Cancer Res (1984) 44:1871-1875.
44. Hunter RL, Olsen MR, Bennett B. Coploymer Adjuvants and TiterMax ®. In: The Theory and Practical Application of Adjuvants. Stewart-Tull DES (Ed), J Wiley & Sons (1995):51-94. Comprehensive text on the historical development of copolymers, leading to development of TiterMax and other emulsion-based adjuvants.
45. Raychaudhuri S, Tonks M, Carbone F, Ryskamp T, Morrow WJW, Hanna N: Induction of antigen-specific class I-restricted cytotoxic T-cells by soluble proteins in vivo. Proc Natl Acad Sci USA (1992) 89:8308-8312.
46. Hariharan K, Braslawsky G, Black A, Raychaudhuri S, Hanna N: The induction of cytotoxic T-cells and tumor regression by soluble antigen formulation. Cancer Res (1995) 55:3486-3489.
47. Sheikh NA, Rajananthanan P, Attard GS, Morrow WJW: Generation of antigen specific CD8+ cytotoxic T-cells following immunization with soluble protein formulated with novel glycoside adjuvants. Vaccine (1999) 17:2974-2982.
48. O'Hagan DT: Recent advances in immunological adjuvants: The development of paniculate antigen delivery systems. Exp Opin Invest Drugs (1998) 7:349-359. A relatively up-to-date compendia detailing current avaliable particulate adjuvant systems focusing in particular upon Chiron's MF59 adjuvant.
49. Ott G, Barchfeld GL, Van Nest G: Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine (1995) 13:1557-1562.
50. Wintsch J, Chaignat CL, Braun DG, Jeannet M, Stalder H, Abrignanl S, Montagna D, Clavijo F, Moret P, Dayer JM, et al: Safety and Immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis (1991) 163:219-225.
51. Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C: Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine (1993) 11:909-913.
52. Ugozzoli M, O'Hagan DT, Ott GS: Intranasal Immunization of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses. Immunology (1998) 93:563-571.
53. Zhu X, Tommasino M, Vousden K, Sadovnikava E, Rappuoli R, Crawford L, Kast M, Melief CJ, Beverley PC, Stauss HJ: Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 In H-2d mice. Scand J Immunol (1995) 42:557-563.
54. Barnett SW, Rajasekar S, Legg H, Doe B, Fuller DH, Haynes JR, Walker CM, Steimer KS: Vaccination with HIV-1 gp120 induces immune responses that are boosted by a recombinant gp120 protein subunit Vaccine (1997) 15:869-873.
55. Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chemoff D: Clinical and immunologie responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis (1994) 170:1288-1291.
56. Langenberg AGM, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L: A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity. Ann Intern Med (1995) 122:889-898.
57. Brey RN: Development of vaccines based on formulations containing non-ionic block copolymers. In: Vaccine Design, the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds), Plenum Press (1995):297-311.
58. Ke Y, McGraw CL, Hunter RL, Kapp JA: Non-ionic triblock copolymers facilitate delivery of exogenous proteins Into the MHC class I and class II processing pathways. Cell Immunol (1997) 176:113-121.
59. Jolies P, Paraf A: Chemical and biological basis of adjuvants. In: Molecular Biology and Biochemistry and Biophysics. Kleinzeller A, Springer G, Wittmann H (Eds), Springer-Verlag (1973):1-153.
60. Wicken A, Knox K: Biological properties of lipotelchoic acids. In: Microbiology. Schlessinger D (Ed), American Society Microbiology (1977):131-154.
61. Schmoika IR: A review of block polymer surfactants. J Am Oil Chem Soc (1977) 54:110-116.
62. Hunter RL, Bennett B: The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octabloack copolymers. J Immunol (1998) 133:3167-3175.
63. Bangham AD, Standish MM, Watkins JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol (1965) 13:238-252.
64. Bangham AD: Membrane models with phospholipids. Prog Biophys Mol Biol (1968) 18:29-95.
65. Gregoriadis G, Leathwood PD: Enzyme entrapment in liposomes. FEBS Lett (1971) 14:95-99. One of the proposals for lipsome entrapment of protein.
66. Papahadjopoulos D, Mayhew E, Poste G, Smith S, Vail WJ: Incorporation of lipid vesicles by mammalian cells provides a potential method for modifying cell behaviour. Nature (1974) 252:163-166.
67. Martin FJ: Stealth liposome technology: An overview. Doxil Clinical Series (1996) 1:1-8.
68. Harding CV, Collins DS, Kanagawa O, Unanue ER: Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J Immunol (1991) 147:2860-2863.
69. Nair S, Zhou X, Huang L, Rouse BT: Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophillc polylysines. J Immunol Methods (1992) 152:237-243. An early work by this group showing that CTL could be induced against soluble protein, the authors hypothesized that alternative antigen-processing pathways to the conventionally accepted cytosolic-baced pathways could be responsible for this nonconventional CTL generation. Further studies by the authors have shown their original premise to be true using in vitro systems.
70. Chen W, Carbone FR, McCluskey J: Electroporation and commercial liposomes efficiently deliver soluble protein Into the MHC class I presentation pathway. Priming in vitro and in vivo for class I-restricted recognition of soluble antigen. J Immunol Methods (1993) 160:49-57.
71. Rao M, matyas GR, Grieder F, Andersen K, Jahrling PB, Alving CR: Cytotoxic T-lymphocytes to Ebola Zaire virus are induced in mice by immunizing with liposomes containing lipid A. Vaccine (1999) 17:2991-2998.
72. Zhou F, Huang L: Liposome-mediated cytoplasmic delivery of proteins: An effective means of accessing the MHC class I-restricted antigen presentation pathway. Immunomethods (1994) 4:229-235.
73. Oakenfull D: Saponins in food: A review. Food Chem (1981) 6:19-40.
74. Price KR, Johnson IT, Fenwick GR: The chemistry and biological significance of saponins in foods and feedingstuffs. Crit Rev Food Sci Nutr (1987) 26:127-135.
75. Kaul PN, Daftari P: Marine pharmacology: Bioactive molecules from the sea. Annu Rev Pharmacol Toxicol (1986) 26:117-142.
76. Espinet RG: Nouveau vaccin antiaphteux a complexe glucoviral. Gac Vet (1951) 13:268-270.
77. Hyslop NSG, Morrow AW: The influence of aluminium hydroxide content, dose volume and the inclusion of saponln on the efficacy of inactivated foot-and-mouth disease vaccines. Res Vet Sci (1969) 10:109-120. Early report describing the adjuvant efffect of saponin.
78. Dalsgard K: Thin layer chromatography fingerprinting of commercially available saponins. Dan Tidsskr Farm (1970) 44:337-331.
79. Dalsgard K, Lovgren K, Stewart-Tull DES: Immunostimulating complexes with Quil A. In: The Theory and Practical Application of Adjuvants. Stewart-Tull DES (Ed), J Wiley & Sons (1995):129-144.
80. Wu JY, Gardner BH, Murphy CI, Seals JR, Kensll CR, Recchia J, Beltz GA, Newman GW, Newman MJ: Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol (1992) 148:1519-1525.
81. Wu JY, Gardner BH, Kushner NN, Pozzi LA, Kensil CR, Cloutier PA, Coughlin RT, Newman MJ: Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes. Cell Immunol (1994) 184:393-406.
82. Lipford GB, Wagner H, Heeg K: Vaccination with immunodomlnant peptides encapsulated In Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T-cells. Vaccine (1994) 12:73-80.
83. Newman MJ, Munroe KJ, Anderson CA, Murphy CI, Panicali DL, Seals JR, Wu JY, Wyand MS, Kensil CR: Induction of antigen-specific killer T-lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant AIDS Res Hum Retroviruses (1994) 10:853-861.
84. Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, Coughlin RT, Powell MF: Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine (1997) 15:1001-1007.
85. Kensil CR, Wu JY, Anderson CA, Wheeler DA, Amsden J: QS-21 and QS-7: Purified saponin adjuvants. Dev Biol Stand (1998) 92:41-47. Comprehensive review illustrating the use of two of the most widely used saponin derivatives as adjuvants.
86. Campbell JB: Saponins. In: The Theory and Practical Application of Adjuvants. Stewart-Tull DES (Ed), J Wiley & Sons (1995):95-127.
87. Bomford R: Saponin and other haemolysins (vitamin A, aliphatic amines, polyene antibiotics) as adjuvants for SRBC In the mouse. Evidence for a role for cholesterol-binding in saponin adjuvanticity. Int Arch Allergy Appl Immunol (1980) 63:170-177.
88. Morein B: The ISCOM: An Immuonstimulating system. Immunol Lett (1990) 25:281-283. A simple description of the potentials of ISCOM use for vaccination.
89. Heeg K, Kuon W, Wagner H: Vaccination of class I major histocompatibllity complex (MHC)-restricted murine CD8+ cytotoxic T-lymphocytes towards soluble antigens: Immunostimulating-ovalbumin complexes enter the class I MHC-antigen pathway and allow sensitization against the immunodominant peptide. Eur J Immunol (1991) 21:1523-1527.
90. Mowatt AM, Donachie AM: ISCOMS - a novel strategy for mucosal immunizations? Immunol Today (1991) 12:383-385.
91. Hsu SC, Schadeck EB, Delmas A, Shaw M, Steward MW: Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. Vaccine (1996) 14:1159-1166.
92. Sambhara S, Woods S, Arpino R, Kurichh A, Tamane A, Bengtsson KL, Morein B, Underdown B, Klein M, Burt D: Influenza (H1N1)-ISCOMs enhance immune responses and protection in aged mice. Mech Ageing Dev (1997) 96:157-169.
93. Villacres MC, Behboudi S, Nikkila T, Lovgren-Bengtsson K, Morein B: Internalization of ISCOM-borne antigens and presentation under MHC-Class I or class II restriction. Cell Immunol (1997) 185:30-38. A finely constructed study showing ISCOM affect upon enhancing both humoral and cell-mediated immune responses. Additionally, the authors showed ISCOM localization within various cellular agtigen-processing compartments leading to the conclusion that ISCOMs did not target particular agtigen processing pathways but acted in a non-specific manner, delivering their load to many different cellular compartments.
94. Keukens EA, de Vrije T, Fabrie CH, Demel RA, Jongen WM, de Kruijff B: Dual specificity of steroi-mediated glycoalkaiold induced membrane disruption. Biochim Biophys Acta (1992) 1110:127-136.
95. Keukens EA, de Vrije T, van den Boom C, de Waard P, Plasman HH, Thiel F, Chupin V, Jongen WM, de Kruijff B: Molecular basis of glycoalkaiold induced membrane disruption. Biochim Biophys Acta (1995) 1240:216-228.
96. Keukens EA, de Vrije T, Jansen LA, de Boer H, Janssen M, de Kroon AI, Jongen WM, de Kruijff B: Glycoalkaiolds selectively permeabllize cholesterol containing biomembranes. Biochim Biophys Acta (1996) 1279:243-250.
97. Rajananthanan P, Attard GS, Sheikh NA, Morrow WJW: Evaluation of novel aggregate structures as adjuvants: Composition, toxicity studies and humoral responses. Vaccine (1999) 17:715-730.
98. Okada H, Toguchi H: Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst (1995) 12:1-99.
99. O'Hagan DT, Jeffery H, Roberts MJ, McGee JP, Davis SS: Controlled release microparticles for vaccine development. Vaccine (1991) 9:768-771.
100. Alpar HO, Almeida AJ, Brown MRW: Microsphere absorption by the nasal mucosa of the rat J Drug Targeting (1994) 2:147-149.
101. Barber BH: The Immunotargeting approach to adjuvant-independent subunlt vaccine design. Semin Immunol (1997) 9:293-301.
102. Kawamura H, Berzofsky JA: Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J Immunol (1986) 136:58-65.
103. Guyre PM, Grazlano RF, Goldstein J, Wallace PK, Morganelli PM, Wardwell K, Howell AL: Increased potency of Fc-receptor targeted antigens. Cancer Immunol Immunother (1997) 45:146-148.
104. Arnon R, Horwitz RJ: Synthetic peptides as vaccines. Curr Opin Immunol (1992) 4:449-453.
105. Partidos CD, Vohra P, Anagnostopoulou C, Jones DH, Farrar GH, Steward MW: Biodegradable microparticles as a delivery system for measles virus cytotoxic T-cell epitopes. Mol Immunol (1996) 33:485-491.
106. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 183:283-287.
107. Fayolle C, Ladant D, Karimova G, Ullmann A, Leclerc C: Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T-cell epitope. J Immunol (1999) 162:4157-4162. One in a series of many studies by this group showing how antigen can be delivered directly into the class I processing pathway using bacterial membrane insertion vector technology.
108. Karimova G, Fayolle C, Ullmann A, Leclerc C, Ladant D: Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: Implication for the in vivo delivery of CD8(+) T-cell epitopes into antigen-presenting cells. Proc Natl Acad Sci USA (1998) 95:12532-12537.
109. Rogel A, Hanski E: Distinct steps in the penetration of adenylate cyclase toxin of Bordetella pertussis into sheep erythrocytes. Translocation of the toxin across the membrane. J Biol Chem (1992) 267:22599-22605.
110. Rogel A, Schultz JE, Brownlie RM, Coote JG, Parton R, Hanski E: Bordetella pertussis adenylate cyclase: Purification and characterization of the toxic form of the enzyme. EMBO J (1989) 8:2755-2760.
111. Hanski E, Fartel Z: Bordetella pertussis invasive adenylate cyclase. Partial resolution and properties of its cellular penetration. J Biol Chem (1985) 260:5526-5532.
112. Otero AS, Yi XB, Gray MC, Szabo G, Hewlett EL: Membrane depolarization prevents cell invasion by Bordetella pertussis adenylate cyclase toxin. J Biol Chem (1995) 270:9695-9697.
113. Weber J, Cheinsong-Popov R, Callow D, Adams S, Patou G, Hodgkin K, Martin S, Gotch F, Kingsman A: Immunogenicity of the yeast recombinant p17/p24: Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine (1995) 13:831-834.
114. Klein MR, Veenstra J, Holwerda AM, Roos MT, Gow I, Patou G, Coutinho RA, De Wolf F, Miedema F: Gag-specific immune responses after immunization with p17/p24: Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses (1997) 13:393-399.
115. Garcia-Valcarcel M, Fowler WJ, Harper DR, Jeffries DJ, Layton GT: Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments of glycoproteln E (gE). Vaccine (1997) 15:709-719.
116. Conner ME, Zarley CD, Hu B, Parsons S, Drabinski D, Greiner S, Smith R, Jiang B, Corsaro B, Baniak V, Madore HP, Crawford S, Estes MK: Virus-like particles as a rotavirus subunit vaccine. J Infect Dis (1996) 174(Suppl 1):S88-S92.
117. Marals D, Passmore JA, Maclean J, Rose R, Williamson AL: A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles. J Gen Virol (1999) 80:2471-2475.
118. Hasan UA, Abal AM, Harper DR, Wren BW, Morrow WJW: Nucleic acid Immunization: Concepts and techniques associated with third generation vaccines. J Immunol Methods (1999) 229:1-22.
119. Ciernik IF, Berzofsky JA, Carbone DP: Induction of cytotoxic T-lymphocytes and antitumor immunity with DNA vaccines expressing single T-cell epitopes. J Immunol (1996) 156:2369-2375.
120. Kuhober A, Pudollek HP, Reifenberg K, Chisari FV, Schlicht HJ, Reimann J, Schirmbeck R: DNA immunization induces antibdy and cytotoxic T-cell responses to hepatitis B core antigen in H-2b mice. J Immunol (1996) 156:3687-3695.
121. Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJP, Brown LE, Suhrbler A: Delivery of multiple CDS cytotoxic T-cell epitopes by DNA vaccination. J Immunol (1998) 160:1717-1723.
122. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretsky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
123. Iho S, Yamamoto T, Takahashi T, Yamamoto S: Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T-cells to induce IFN-γ production in vitro. J Immunol (1999) 163:3642-3652.
124. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol (1998) 160:870-876.
125. Lanzavecchia A: Mechanisms of antigen uptake for presentation. Curr Opin Immunol (1996) 8:348-354. Informative review detailing the concept of how DCs are able to function as both antigen processors and antigen presenters depending on their maturation stage.
126. Austyn JM: New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med (1996) 163:1287-1292.
127. Lanzavecchia A: Immunology. Licence to kill. Nature (1998) 393:413-414.
128. Citterio S, Rescigno M, Foti M, Granucci F, Aggujaro D, Gasperi C, Matyszak MK, Girolomoni G, Ricciardi-Castagnoli P: Dendritic cells as natural adjuvants. Methods (1999) 19:142-147. A simple review showing the potential of DCs as cencer immunotherapy strategies, as well as detailing methods to purify, expand and mature DCs in vitro. Ricciardi-Castagnoli has published a series of papers in the field of DC research, in particular citing their use as adjuvants.
129. Schnell S, Young JW, Houghton AN, Sadelain M: Retrovirally transduced mouse dendritic cells require CD4+ T-cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells. J Immunol (2000) 164:1243-1250.
130. Wang H, Griffiths MM, Burton DR, Ghazal P: Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA (2000) 97:847-852.
131. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taldi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med (1996) 2:52-58.
132. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med (1998) 3:328-332
133. Thumer B, Haendle I, Roder C, Dieckmann D, Kelkavoussi P, Jonuteit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 190:1669-1678. Incisive and detailed report on a clinical trial using DCs as a vaccination therapy. The authors showed that this strategy was able to regress turnors and that this was due in part to CD8+ CTL infiltrates.
134. Matthews DJ, Emson CL, McKenzle GJ, Jolin HE, Blackwell JM, McKenzle AN: IL-13 is a susceptibility factor for Lelshmania major infection. J Immunol (2000) 164:1458-1462.
135. Baszler TV, Long MT, McElwain TF, Mathison BA: Interferon-γ and interleukin-12 mediate protection to acute Neospora caninum infection in BALB/c mice. Int J Parasitol (1999) 29:1635-1646.
136. Leal IS, Smedegard B, Andersen P, Appelberg R: Interleukin-6 and Interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect Immun (1999) 67:5747-5754.
137. el-Shami KM, Tzehoval E, Vadai E, Feldman M, Eisenbach L: Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. J Interferon Cytokine Res (1999) 19:1391-1401.
138. Viney JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA: Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol (1998) 160:5815-5825.
139. Esche C, Subbotin VM, Hunter O, Peron JM, Maliszewski C, Lotze MT, Shurin MR: Differential regulation of epidermal and dermal dendritic cells by IL-12 and Fits ligand. J Invest Dermatol (1999) 113:1028-1032.
140. McKenna HJ: Generating a T-cell tumor-specific immune response In vivo: Can flt3-ligand-generated dendritic cells tip the balance? Cancer Immunol Immunother (1999) 48:281-286.
141. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, Guha C: Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res (1999) 59:6028-6032.
142. Braun SE, Chen K, Blazar BR, Orchard PJ, Sledge G, Robertson MJ, Broxmeyer HE, Cometta K: Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther (1999) 10:2141-2151.
143. Williamson E, Westrich GM, Viney JL: Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol (1999) 163:3668-3675.
144. H2 cells: Differential patterns of lymphokine secretion lead to differential functional properties. Annu Rev Immunol (1989) 7:145-173.
145. Mosmann TR, Li L, Sad S: Functions of CDS T-cell subsets secreting different cytokine patterns. Semin Immunol (1997) 9:87-92. A comprehensive review of T-cell cytokine-secreting patterns and their function.
146. Bukreyev A, Whitehead SS, Bukreyeva N, Murphy BR, Collins PL: Interferon γ expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc Natl Acad Sci USA (1999) 96:2367-2372.
147. Tang YW, Graham BS: Interleukln-12 treatment during immunization elicits a T-helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. J Infect Dis (1995) 172:734-738.
148. Tang YW, Graham BS: T-cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest (1997) 99:2183-2191.
149. Tang YW, Graham BS: Anti-IL-4 treatment at immunization modulates cytoklne expression, reduces illness, and increases cytotoxic T-lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest (1994) 94:1953-1958. One of a number of studies by Tang and Graham detalling how the Th1/Th2 balance can be manipulated to influence the immune response to a vaccine.
150. Aung S, Tang YW, Graham BS: Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. J Virol (1999) 73:8944-8949.
151. Yusibov V, Shivprasad S, Turpen TH, Dawson W, Koprowski H: Plant viral vectors based on tobamoviruses. Curr Top Microbiol Immunol (1999) 240:81-94.
152. Redman TK, Harmon CC, Michalek SM: Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A of Streptococcus sobrinus: Persistence and induction of humoral responses in rats. Infect Immun (1994) 62:3162-3171.
153. Berggren RE, Wunderlich A, Ziegler E, Schleicher M, Duke RC, Looney D, Fang FC: HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 10:489-495.
154. Gomez-Duarte OG, Bumann D, Meyer TF: The attenuated Salmonella vaccine approach for the control of Hellcobacter pylori-related diseases. Vaccine (1999) 17:1667-1673.
155. Mason HS, Lam DM-K, Arntzen CJ: Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA (1992) 87:11745-11749. First report of the production of foreign protein by a plant for use as an immunogen.
156. MoGarvey PB, Hammond J, Dlenelt MM, Hooper DC, Fu ZF, Dietzschold B, Koprowski H, Michaels FH: Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology (1995) 13:1484-1487.
157. Haq TA, Mason HS, Clements JD, Amtzen CJ: Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 268:714-716.
158. Castanon S, Marin MS, Martin-Alonso JM, Boga JA, Casals R, Humara JM, Ordas RJ, Parra F: Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J Virol (1999) 73:4452-4455
159. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ: Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenlcity in mice. Proc Natl Acad Sci USA (1996) 93:5335-5340
160. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letelller M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB: A plant-derived edible vaccine against hepatitis B virus. FASEB J (1999) 13:1796-1799.
161. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Amtzen CJ: Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature Med (1998) 4:607-609. NIH sponsored phase I 'proof-of-concept' clinical trial using potatoes expressing Escherichia coll toxin as an immunogen. Subjects were fed raw potato and then studied for both serum and stool antibody responses - Indicative of systemic and localized mucosal responses.
162. Wigdorovitz A, Perez Filguelra DM, Robertson N, Carrillo C, Sadir AM, Morris TJ, Borca MV: Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1. Virology (1999) 264:85-91.